These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 20841940)

  • 1. [Availability evaluation of closed systems by using practical training kits for preparation of antitumor drugs].
    Sato J; Odagiri N; Terui K; Iwasaki Y; Hosoya E; Hayakari M
    Gan To Kagaku Ryoho; 2010 Sep; 37(9):1753-7. PubMed ID: 20841940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device.
    Siderov J; Kirsa S; McLauchlan R
    J Oncol Pharm Pract; 2010 Mar; 16(1):19-25. PubMed ID: 19965949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment.
    Yoshida J; Tei G; Mochizuki C; Masu Y; Koda S; Kumagai S
    Ann Occup Hyg; 2009 Mar; 53(2):153-60. PubMed ID: 19261696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A test method for assessment of spill and leakage from drug preparation systems.
    Nygren O; Gustavsson B; Eriksson R
    Ann Occup Hyg; 2005 Nov; 49(8):711-8. PubMed ID: 16126763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost savings realized by use of the PhaSeal(®) closed-system transfer device for preparation of antineoplastic agents.
    Edwards MS; Solimando DA; Grollman FR; Pang JL; Chasick AH; Hightman CM; Johnson AD; Mickens MG; Preston LM
    J Oncol Pharm Pract; 2013 Dec; 19(4):338-47. PubMed ID: 23975556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safe Cytotoxic Drug Preparation Using Closed-system Transfer Device: Technical and Practical Evaluation of a New Device (Vialshield/Texium) Comparatively to a Reference One (Phaseal).
    Garrigue P; Montana M; Ventre C; Savry A; Gauthier-Villano L; Pisano P; Pourroy B
    Int J Pharm Compd; 2016; 20(2):148-54. PubMed ID: 27323425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan.
    Yoshida J; Koda S; Nishida S; Yoshida T; Miyajima K; Kumagai S
    J Oncol Pharm Pract; 2011 Mar; 17(1):29-38. PubMed ID: 20699333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a closed drug preparation method for oral anticancer drugs.
    Wakui N; Ookubo T; Iwasaki Y; Ito R; Saito K; Nakazawa H
    J Oncol Pharm Pract; 2013 Dec; 19(4):315-20. PubMed ID: 23292970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spill and leakage using a drug preparation system based on double-filter technology.
    Nygren O; Olofsson E; Johansson L
    Ann Occup Hyg; 2008 Mar; 52(2):95-8. PubMed ID: 18216371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a closed-system drug transfer device (PhaSeal) and impact on preparation time.
    Sánchez-Rubio Ferrández J; Lozano MC; Iglesias I; Sánchez-Rubio Ferrández L; Rodríguez Vargas B; Moreno Díaz R
    Int J Pharm Compd; 2012; 16(5):431-3. PubMed ID: 23072203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PhaSeal® system: impact of its use on workplace contamination and duration of chemotherapy preparation.
    Favier B; Labrosse H; Gilles-Afchain L; Cropet C; Perol D; Chaumard N; Latour JF; Hild P
    J Oncol Pharm Pract; 2012 Mar; 18(1):37-45. PubMed ID: 21422148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of surface contamination in a hospital hematology--oncology pharmacy.
    Touzin K; Bussières JF; Langlois E; Lefebvre M
    J Oncol Pharm Pract; 2009 Mar; 15(1):53-61. PubMed ID: 18772214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Measures of preventing occupational exposure to hazardous drugs-based on new insights].
    Sugiura S; Gohma H; Hamajima N
    Gan To Kagaku Ryoho; 2014 Aug; 41(8):923-5. PubMed ID: 25132022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of two closed-system drug transfer device in the antineoplastic drug elaboration process].
    Gómez-Álvarez S; Porta-Oltra B; Hernandez-Griso M; Pérez-Labaña F; Climente-Martí M
    Farm Hosp; 2016 Jan; 40(1):36-43. PubMed ID: 26882832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug supply by ration kits: report of an evaluation.
    Essent Drugs Monit; 1991; (11):12-4. PubMed ID: 12284332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden.
    Hedmer M; Georgiadi A; Bremberg ER; Jönsson BA; Eksborg S
    Ann Occup Hyg; 2005 Oct; 49(7):629-37. PubMed ID: 16126760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of prescription practices and of the rational use of medicines in Niger].
    Mallet HP; Njikam A; Scouflaire SM
    Sante; 2001; 11(3):185-93. PubMed ID: 11641083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug stability and compatibility in oncology care.
    Williams DA
    J Infus Chemother; 1996; 6(4):195-202. PubMed ID: 9229315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators.
    Crauste-Manciet S; Sessink PJ; Ferrari S; Jomier JY; Brossard D
    Ann Occup Hyg; 2005 Oct; 49(7):619-28. PubMed ID: 16126757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Verification of reduction in preparation time and cost of cyclophosphamide when using the closed-system drug transfer device].
    Ikeno Y; Arii D; Nakajima H; Murooka K; Nojima M; Kidokoro A
    Gan To Kagaku Ryoho; 2014 May; 41(5):611-5. PubMed ID: 24917007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.